Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
暂无分享,去创建一个
P. Thall | Y. Oki | E. Shpall | B. Andersson | B. Valdez | Y. Nieto | U. Popat | M. Qazilbash | C. Pinnix | Junsheng Ma | A. Alousi | R. Champlin | S. Milgrom | B. Dabaja | M. Fanale | Roy B. Jones | P. Anderlini | C. Hosing | P. Kebriaei | Alan L. Myers | A. Gulbis | Melissa Timmons | Saira S. Ahmed
[1] M. Shipp,et al. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] S. Parmar,et al. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. , 2017, The Lancet. Haematology.
[3] O. Casasnovas,et al. Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] K. Savage,et al. Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study , 2016, The Lancet. Oncology.
[5] G. Salles,et al. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group , 2016, Haematologica.
[6] A. Nademanee,et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial , 2015, The Lancet.
[7] A. Zelenetz,et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. , 2015, The Lancet. Oncology.
[8] S. Parmar,et al. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[9] P. Thall,et al. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[10] D. Murray,et al. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. , 2012, Experimental hematology.
[11] A. Zelenetz,et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. , 2012, Blood.
[12] A. Zelenetz,et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. , 2010, Blood.
[13] A. Zelenetz,et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Klemens Scheidhauer,et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Garcia-conde,et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] Dirk Hasenclever,et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial , 2002, The Lancet.
[18] W. Plunkett,et al. Gemcitabine: preclinical pharmacology and mechanisms of action. , 1996, Seminars in oncology.
[19] G. Peters,et al. Schedule-dependent antitumor effect of gemcitabine in in vivo model system. , 1995, Seminars in oncology.
[20] R. Larsson,et al. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. , 1995, Seminars in oncology.
[21] D. Winfield,et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial , 1993, The Lancet.
[22] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .